Memphis scientists instrumental in new, landmark COVID drug
‘This is the last piece of the puzzle’
Certified Medical Assistant Jaimee Lapham (left) administers a COVID-19 test on Jan. 11, 2022, at the drive-thru testing site at Collierville High School. COVID is still killing 450 Americans a day, about one 9/11 every four days. (Mark Weber/The Daily Memphian file)
The next possible landmark COVID drug is so rich in Memphis DNA that if approved by the FDA, patent royalty checks will immediately flow to town. Plus, it’s in capsule form, taken once a day for 21 days. It does not need to be refrigerated and can be shipped easily and inexpensively around the world.
Topics
UTHSC Mitchell Steiner GTx COVID-19 sabizabulin Subscriber Only2025 is almost over. Now is the time to support your trusted local news source.
Will you help us reach more Memphians with quality, in-depth local news? Make a fully tax-deductible donation or other contribution to The Daily Memphian, a 501(c)3 nonprofit news organization, today.
Thank you for keeping up with what’s happening in Memphis. Thank you for investing in our community’s trusted local news source.
Jane Roberts
Jane Roberts has reported in Memphis for more than 20 years. As a senior member of The Daily Memphian staff, she was assigned to the medical beat during the COVID-19 pandemic. She also has done in-depth work on other medical issues facing our community, including shortages of specialists in local hospitals. She covered K-12 education here for years and later the region’s transportation sector, including Memphis International Airport and FedEx Corp.
Comments
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.